euroVeda – Schizophrenia Therapy
Innovator ID
SNDMAC016
Non-invasive intranasal Iloperidone nanoemulsion delivering targeted brain therapy for schizophrenia, improving efficacy, comfort, and long-term patient adherence.
Schizophrenia affects over 24 million individuals globally, yet long-term antipsychotic therapy often results in poor patient adherence due to side effects and invasive treatment routes. Oral Iloperidone has only ~36% brain availability, leading to high systemic exposure and side effects, while injectable formulations are painful and reduce compliance. Half of all patients relapse due to inconsistent treatment adherence, worsening functional outcomes for patients and increasing caregiver and societal burden. There is a crucial unmet medical need for a non-invasive, brain-targeted treatment that improves efficacy while minimizing side effects and supporting long-term therapy.
NeuroVeda delivers Iloperidone directly to the brain through a mucoadhesive intranasal nanoemulsion, enhancing brain bioavailability while reducing systemic toxicity. The formulation is painless, patient-friendly, improves therapeutic effect, and promotes treatment continuity, reducing relapse risk and improving quality of life.
Primary customers include psychiatric hospitals, neuropsychiatric clinics, rehabilitation centers, neurologists, and psychiatrists treating schizophrenia and related disorders. Secondary customers include pharmaceutical companies interested in licensing the formulation platform, government mental health programs, and patient support organizations promoting non-invasive therapies. Patients and caregivers also directly benefit through improved comfort, safety, and adherence.
NeuroVeda enhances treatment outcomes by improving drug delivery to the brain while minimizing systemic side effects, offering a better therapeutic experience compared to oral and injectable options. Hospitals and clinics benefit from improved patient adherence and reduced relapse-related hospitalizations. Pharmaceutical companies gain a scalable drug delivery platform that can be adapted for multiple CNS drugs. Patients and families benefit through improved daily functioning, comfort, and quality of life. The innovation reduces long-term care burden and supports more stable mental health outcomes.
We Would Require Support In the Following :
Technical and Product Development Support; Infrastructure and Prototyping Facilities; Funding and Financial Assistance; Networking, Collaboration, and Investor Connect; Market Research and Business Planning Support
Capital to achieve the desired outcome, we would require
₹50–75 L, partial
And would be required for
Research, Design & Validation Funding; Prototype Development Support; Pilot Testing and Field Trial Support; Business Model & Market Access Support
Expected Return Should Be in:
Less than 3 years